P/B
1,1
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
$19.5M
Market Cap • 9/25/2026
2021
(5 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
Australia
Country
Valuation
P/S
10,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,6
EPS
—
Market Cap
Market Cap
19,5M
EV
15M
EV/Revenue
7,8
EV/EBITDA
-0,4
EV/EBIT
-0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-125%
Total Yield
-125%
Payout
0%
Retained Earnings
-138M
Profitability
Gross Margin
9,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
1805,1%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,1
Debt/Equity
0%
Current Ratio
1,2
Quick Ratio
1,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!